Milestone Launches First-in-Class PSVT Treatment, Faces Coverage Hurdles
Event summary
- Milestone Pharmaceuticals launched CARDAMYST™ (etripamil) nasal spray, the first FDA-approved self-administered treatment for paroxysmal supraventricular tachycardia (PSVT), on January 26, 2026.
- The FDA approved CARDAMYST on December 12, 2025, marking the first approval in over 30 years for this condition.
- Milestone plans to deploy a national sales force in mid-February 2026 and expects a $25 copay cap for eligible insured patients.
- The company is implementing a patient assistance program to support benefits verification and reimbursement.
The big picture
CARDAMYST addresses a significant unmet need in the treatment of PSVT, a condition often managed through costly and inconvenient emergency room visits or invasive procedures. The lack of recent innovation in this space creates an opportunity for Milestone, but the company faces the common challenge of securing payer coverage for novel therapies. The $25 copay cap suggests an aggressive strategy to drive initial adoption, but long-term profitability depends on broader insurance acceptance.
What we're watching
- Coverage Dynamics
- The success of CARDAMYST hinges on securing broad formulary coverage and favorable reimbursement rates, which will dictate patient access and revenue generation.
- Market Penetration
- The effectiveness of Milestone’s national sales force and patient assistance program will determine the speed and extent of market penetration within the estimated 2 million PSVT sufferers in the U.S.
- Pipeline Risk
- Milestone’s future growth is tied to the progress of etripamil in Phase 2 pediatric PSVT and Phase 3 AFib-RVR trials, introducing pipeline risk if these programs encounter setbacks.
Related topics